Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update - PubMed (original) (raw)
Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update
Robert G Hart et al. Stroke. 2017 Apr.
Abstract
Background and purpose: Embolic stroke of undetermined source (ESUS) designates patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke mechanism. It has been hypothesized that anticoagulation is more efficacious than antiplatelet therapy for secondary stroke prevention in ESUS patients. We review available information about ESUS.
Methods: Systematic literature review to assess the frequency of ESUS, patient features, and prognosis using PubMed from 2014 to present, unrestricted by language.
Results: On the basis of 9 studies, the reported frequency of ESUS ranged from 9% to 25% of ischemic strokes, averaging 17%. From 8 studies involving 2045 ESUS patients, the mean age was 65 years and 42% were women; the mean NIH stroke score was 5 at stroke onset (4 studies, 1772 ESUS patients). Most (86%) ESUS patients were treated with antiplatelet therapy during follow-up, with the annualized recurrent stroke rate averaging 4.5% per year during a mean follow-up of 2.7 years (5 studies, 1605 ESUS patients).
Conclusions: ESUS comprises about 1 ischemic stroke in 6. Patients with ischemic stroke meeting criteria for ESUS were relatively young compared with other ischemic stroke subtypes and had, on average, minor strokes, consistent with small emboli. Retrospective methods of available studies limit confidence in stroke recurrence rates but support a substantial (>4% per year) rate of stroke recurrence during (mostly) antiplatelet therapy. There is an important need to define better antithrombotic prophylaxis for this frequently occurring subtype of ischemic stroke.
Keywords: diagnosis; embolism; prognosis; secondary prevention; stroke.
© 2017 American Heart Association, Inc.
Similar articles
- Thrombolysis for acute ischaemic stroke.
Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Wardlaw JM, et al. Cochrane Database Syst Rev. 2003;(3):CD000213. doi: 10.1002/14651858.CD000213. Cochrane Database Syst Rev. 2003. PMID: 12917889 Updated. - Anticoagulants for acute ischaemic stroke.
Wang X, Ouyang M, Yang J, Song L, Yang M, Anderson CS. Wang X, et al. Cochrane Database Syst Rev. 2021 Oct 22;10(10):CD000024. doi: 10.1002/14651858.CD000024.pub5. Cochrane Database Syst Rev. 2021. PMID: 34676532 Free PMC article. - Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
Bala MM, Celinska-Lowenhoff M, Szot W, Padjas A, Kaczmarczyk M, Swierz MJ, Undas A. Bala MM, et al. Cochrane Database Syst Rev. 2017 Oct 2;10(10):CD012169. doi: 10.1002/14651858.CD012169.pub2. Cochrane Database Syst Rev. 2017. PMID: 28968483 Free PMC article. Updated. - A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. Clegg A, et al. Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068 - Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Kwan J, Hafdi M, Chiang LLW, Myint PK, Wong LS, Quinn TJ. Kwan J, et al. Cochrane Database Syst Rev. 2022 Jul 14;7(7):CD012269. doi: 10.1002/14651858.CD012269.pub2. Cochrane Database Syst Rev. 2022. PMID: 35833913 Free PMC article.
Cited by
- Prolonged ECG with a novel recorder utilizing electrode belt and mobile device in patients with recent embolic stroke of undetermined source: A pilot study.
Lumikari TJ, Pirinen J, Putaala J, Sibolt G, Kerola A, Pakarinen S, Lehto M, Nieminen T. Lumikari TJ, et al. Ann Noninvasive Electrocardiol. 2020 Nov;25(6):e12802. doi: 10.1111/anec.12802. Epub 2020 Sep 27. Ann Noninvasive Electrocardiol. 2020. PMID: 32981209 Free PMC article. - Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios Are Associated with Recurrent Ischemic Stroke in Patients with Embolic Stroke of Undetermined Source.
Li TYW, Sia CH, Chan BPL, Ho JSY, Leow AS, Chan MY, Kojodjojo P, Galupo MJ, Teoh HL, Sharma VK, Seet RCS, Yeo LLL, Tan BY. Li TYW, et al. J Stroke. 2022 Sep;24(3):421-424. doi: 10.5853/jos.2022.00486. Epub 2022 Sep 30. J Stroke. 2022. PMID: 36221946 Free PMC article. No abstract available. - Potential Embolic Sources in Embolic Stroke of Undetermined Source Patients with Patent Foramen Ovale.
Toh KZX, Koh MY, Ho JSY, Ong KHX, Lee YQ, Chen X, Fang JT, Chong EY, Lim ICZY, Teo YH, Teo YN, Chua CYK, Lim Y, Chan BPL, Sharma VK, Yeo LLL, Sia CH, Tan BYQ. Toh KZX, et al. Cerebrovasc Dis. 2023;52(5):503-510. doi: 10.1159/000527791. Epub 2022 Dec 1. Cerebrovasc Dis. 2023. PMID: 36455524 Free PMC article. - Outcome after intravenous thrombolysis in embolic stroke of undetermined source compared to cardioembolic stroke.
Zivanovic Z, Ostojic Z, Rajic S, Vlahovic D, Mijajlovic M, Jovicevic M. Zivanovic Z, et al. Wien Klin Wochenschr. 2020 Sep;132(17-18):515-520. doi: 10.1007/s00508-020-01727-5. Epub 2020 Sep 2. Wien Klin Wochenschr. 2020. PMID: 32876739 - Atherosclerosis as a Potential Cause of Deep Embolic Stroke of Undetermined Source: A 3T High-Resolution Magnetic Resonance Imaging Study.
Luo N, Shang ZY, Tao L, Yang BQ, Chen HS. Luo N, et al. J Am Heart Assoc. 2022 Nov;11(21):e026737. doi: 10.1161/JAHA.122.026737. Epub 2022 Oct 27. J Am Heart Assoc. 2022. PMID: 36300665 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical